الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
HCC is one of the most serious complications of liver cirrhosis. The incidence of HCC in individuals with HCV cirrhosis is 3–5% per year. Therefore, evaluation of biomarkers that predict early occurrence of HCC in patients with hepatitis C virus (HCV) induced liver cirrhosis is of great clinical value from the diagnostic and prognostic points of view.
As for patient infected with HBV, they are more prone to develop HCC than those infected with HCV. Therefore, evaluation of biomarkers that predict early occurrence of HCC in those patients is also of great importance.
AFP has been utilized as a marker for HCC, despite its low sensitivity and positive predictive value. Moreover, it has been estimated that up to 30% of HCC patients have normal α-fetoprotein levels. Therefore, novel biomarkers are needed to be used for early detection of cases with HCC.
Endoglin is a useful serum marker for HCC which can be used as marker of diagnosis and prognosis as well. It is only weakly expressed in normal tissues, but strongly expressed in tumor endothelia.
The present study was held to study the changes in serum Endoglin in HCV and HBV induced liver cirrhosis and HCC and to evaluate its role as an emerging novel biomarker of HCC in comparison to AFP and GGT.
The study was conducted on 80 subjects in Alexandria Main University Hospital, Tropical Medicine Department, the subjects were divided into two groups. group I consisted 30 patients with HCV and HBV induced liver cirrhosis without HCC while group II contained 50 patients with HCV and HBV induced HCC.
Patients with concurrent autoimmune conditions, pulmonary disease, fever, alcohloics and other malignancies were excluded from the study.